An Inquiry Into Prophylactic Treatment Patterns by Migraine Diagnosis: The AMEND Study

Anoop K. Reddy,1 Amanda Policastro,2 Albert Reppine,3 John Sekab,4 Chris Purdy,2 Laura Dalfonso,1 Raf Magar2

Affiliations:1 Anoop Reddy Private Practice, Tampa, FL; 2Neurosciences, Allergan, Inc.; 3AHRM Inc., Buffalo, NY

RESULTS

Demographics

Of the 61 patients who received onabotulinumtoxinA at the first visit, 78.6% of CM and non-CM patients (361/459) were seen at least once during the study period

Assessments

• The diagnosis, number of headache days, and prophylactic medication use were recorded at the first visit and the most recent visit
• Number of headache days was also collected at the highest headache count visit if that visit did not equal the first or most recent visit
• Demographic and collected variables were analyzed using descriptive statistics (SAS V9.2) with no imputation for missing data

Table 1. Primary Headache Diagnosis at Most Recent Visit

Table 2. Summary of Headache Days at the Highest Headache Count Visit

Table 3. Prophylactic Medications at First Visit and Most Recent Visit

Table 4. Most Common Alternative Prophylactic Medications

REFERENCES

2. BOTREM® (onabotulinumtoxinA) for Injection, for Intramuscular, Intradermal, or Intrathecal Use. Full Prescribing Information. Irvine, CA, USA. 2014.

DISCLOSURES

Financial arrangements of the authors with companies whose products may be included in the present manuscript disclosure: None for the authors. J. Sekab: non-commercial support from Allergan. A. Policastro: non-commercial support from Allergan. A. Reppine: non-commercial support from Allergan. C. Purdy: non-commercial support from Allergan. L. Dalfonso: non-commercial support from Allergan. R. Magar: non-commercial support from Allergan. G. Riley, F. Udina: non-commercial support from Allergan. A. Reddy: non-commercial support from Allergan. M. Vanek: non-commercial support from Allergan. M. Schuler: non-commercial support from Allergan. S. Sokolowski: non-commercial support from Allergan. A. Pacha: non-commercial support from Allergan.

ACKNOWLEDGMENTS

This study was sponsored by Allergan, Inc., Irvine, CA. Writing and editorial assistance and/or preparation of the manuscript was provided to the authors by Kris Schuler of Complete Healthcare Communications (Chadds Ford, PA) and Allergan employees at AHRM Inc. The authors received no financial compensation for their authorship. Chris Purdy, Amanda Policastro, and Raf Magar are employees of AHRM Inc.

To obtain a PDF of this article, please visit www.allergencore.com/P07133

Changepress may apply for personal information is shared.

Presented at the 67th American Academy of Neurology Annual Meeting (AAN), April 18–25, 2015, Washington, DC.

P3.042